Mallinckrodt (MNK) M&A Announcement summary

Deal rationale and strategic fit

• The merger creates a global, scaled, and diversified pharmaceuticals leader with complementary branded and generics portfolios, enhancing patient access, innovation, and commercial position.

• The combined entity will have strengths in rare diseases, sterile injectables, and generics, with a robust U.S.-focused footprint including 17 manufacturing facilities, 30 distribution centers, and 5,700 employees.

• The merged company will establish two focused businesses: a scaled brands business and a sterile injectables/generics business, with plans for future separation subject to board approval.

• The transaction aims to unlock value, expand therapeutic reach, and enable investment in innovation, business development, and future M&A.

• Leadership will include executives and directors from both companies, with global headquarters in Dublin, Ireland.

Financial terms and conditions

• Endo shareholders receive $80 million in cash (subject to adjustment) and 49.9% pro forma ownership; Mallinckrodt shareholders hold 50.1%.

• Implied pro forma enterprise value is $6.7 billion, with projected 2025 revenue of $3.6 billion and Adjusted EBITDA of $1.2 billion at a 34% margin.

• The deal is financed with cash on hand and $900 million in committed financing for Endo from Goldman Sachs.

• Pro forma total debt is $3.4 billion and net debt is $2.8 billion, with pro forma leverage of 2.3x.

• Mallinckrodt's senior secured debt will be refinanced; Endo's debt remains outstanding.

Synergies and expected cost savings

• At least $150 million in annual pre-tax run rate synergies are expected by year three, with $75 million in the first year.

• Synergies will primarily come from infrastructure, resource optimization, and integration of business functions, not from sales force reductions.

• Enhanced purchasing power, elimination of overlapping roles, and R&D savings from economies of scale are key drivers.